2024 Targeted Therapies for Lung Cancer (TTLC) - Abstracts & Posters-PP01.04 Al-Obeidi

PP01.04 Al-Obeidi - Abstract

Pdf Summary

This document presents a cohort study evaluating the impact of loss of function ARID1A mutations on the efficacy of immune checkpoint inhibitor (ICI) therapy in patients with stage IV non-small cell lung cancer (NSCLC). The study included 85 patients with ARID1A mutations and 254 patients with wild-type ARID1A. Patients with ARID1A mutations were more likely to be Black, former smokers, younger than 65, and have high tumor PD-L1 expression. They were also less likely to have EGFR and KEAP1 mutations but more likely to have KRAS G12C mutations. Patients with ARID1A mutations who received ICI showed a statistically significant improvement in progression-free survival (PFS), with a 4-month increase in median PFS. However, there was no significant difference in overall survival (OS) between the two groups. When patients with oncogene-driven NSCLC were excluded from the analysis, the numerical difference in PFS and OS was not statistically significant. The study suggests that ARID1A mutations may be a predictive biomarker for ICI therapy in NSCLC, but larger prospective studies are needed to confirm these findings. Further research on ARID1A as a composite biomarker in combination with other predictors is warranted.

Keywords

cohort study

ARID1A mutations

immune checkpoint inhibitor

non-small cell lung cancer

PD-L1 expression

EGFR mutations

KEAP1 mutations

KRAS G12C mutations

progression-free survival

overall survival